Claryx Raises $3.5M Pre-Seed for Hospital Genomic Surveillance

Claryx, a New York genomic intelligence company, emerged from stealth on August 4, 2026, with a $3.5M Pre-Seed round led by Outlander VC. Company Ventures, Boost VC, Neon, Mana Ventures, 640 Oxford, and Precursor also participated.

The company is building what it calls the hospital immune system: a managed surveillance platform that sequences confirmed patient infections, connects related cases, and compares them with samples from air, sinks, wastewater, surfaces, and equipment. The objective is to help hospital infection-prevention teams find transmission earlier, identify likely environmental reservoirs, and verify whether an intervention stopped the spread.

The funding matters because healthcare-associated infections remain both a clinical threat and an operating problem. The CDC reports that roughly 1 in 38 U.S. hospital patients has at least one such infection on any given day. Claryx is betting that continuous genomic intelligence can turn a slow, fragmented detection process into an operational system hospitals can use before scattered cases become an obvious outbreak.

What Happened

In its official funding announcement, Claryx said the $3.5M round will support a company already live across multiple health systems. It did not identify those customers, publish a deployment count, or provide a detailed use-of-funds allocation. The financing is therefore best understood as capital behind a commercial and scientific thesis, not proof that hospital-wide genomic surveillance has already become a standard line item.

Brothers Kurt Hackenberger and Dirk Hackenberger founded Claryx around a family experience. In 2004, their grandmother entered a hospital for a routine procedure, contracted C. difficile, developed sepsis, and spent 3 months there. Their family never received a clear answer about where the infection came from. The company is built around making that answer available while an intervention can still change what happens next.

Kurt Hackenberger is Claryx's Co-Founder and CEO. He previously worked in investing, most recently as a Vice President at The Carlyle Group. Dirk Hackenberger, PhD, is Co-Founder and Chief Science Officer, with doctoral research focused on infectious-disease genomics and antimicrobial resistance. Claryx combines those two disciplines: scientific resolution and an operating model that hospitals can afford to run.

How Claryx Works

Hospital outbreaks are often detected through case counts and statistical thresholds. That approach can miss transmission spread across units, where a few cases in several wards may never look like a single outbreak. Claryx is designed to connect those cases using genomic evidence instead of waiting for the pattern to become obvious in aggregate.

The company's CloneLink platform compares the genomes of confirmed patient infections with other clinical cases and environmental metagenomes at strain level. Environmental sampling can include air, wastewater, sinks, equipment, and high-touch surfaces. AeroScan provides continuous air sampling in higher-risk areas, while CloneLink surfaces matches intended to help infection-prevention teams decide where to investigate and intervene.

Claryx says its proprietary chemistry reduces the most expensive sequencing step by more than 20x. That is a company-reported claim, but it speaks directly to the commercial question. Sequencing a difficult case after an outbreak is valuable. Running genomic surveillance continuously across a hospital requires a different cost structure, predictable operations, and signals precise enough to support action without flooding already stretched teams.

Why the Evidence Matters

Claryx's approach sits on top of a growing evidence base for real-time genomic surveillance. The company cites a two-year University of Pittsburgh study at UPMC Presbyterian, published in Clinical Infectious Diseases, that identified 172 otherwise undetected outbreaks across 476 patients. 96% of traced transmission routes that were acted on went no further.

The same analysis estimated that the program avoided 62 infections and close to five deaths over two years, while generating a 3.2x return on program cost. Those results belong to the published surveillance program and should not be confused with outcomes from Claryx's undisclosed health-system deployments. That distinction is important because strong category evidence creates an opportunity, but the company must still prove its own execution, reliability, and economics.

The evidence also changes how this market should be evaluated. The value is not merely another infection dashboard. It is the ability to establish whether cases are connected, identify a likely reservoir, direct an intervention, and confirm that transmission stopped. Hospitals already spend heavily on the downstream consequences of infections. Claryx is trying to move some of that spending toward earlier, more precise prevention.

Why Investors Backed the Round

Outlander VC led a syndicate that spans early-stage technology investors. The investor logic appears to rest on a combination of founder fit, proprietary science, a costly institutional problem, and the possibility of a repeatable service model. Claryx is not selling a single test. It is attempting to become a continuous intelligence layer inside hospital infection-prevention operations.

The founder pairing strengthens that case. Kurt Hackenberger brings experience assessing technology businesses and allocating capital. Dirk Hackenberger brings the scientific background behind the sequencing chemistry and genomic methods. That does not remove clinical, regulatory, privacy, or adoption risk, but it gives the company a leadership structure aligned with both the technology and the economics it must prove.

The round also reflects a wider shift in healthcare technology investment. Capital is moving toward systems that connect scientific advances with measurable operating outcomes. In Claryx's case, the outcomes hospitals care about include fewer infections, faster interventions, freed bed capacity, lower unreimbursed costs, and better evidence that infection-control work actually succeeded.

What This Signals for Hospital Operations

The most consequential part of Claryx's story is not the $3.5M headline. It is the argument that genomic surveillance can become routine infrastructure. Hospitals have long used sequencing to investigate difficult outbreaks, but continuous monitoring changes the operating posture from forensic response toward earlier detection and confirmation.

That transition will not be automatic. Claryx must demonstrate that its signals remain accurate across varied hospital environments, that workflows fit infection-prevention teams, that privacy and security controls meet institutional requirements, and that the financial case survives beyond a pilot. It must also show results from its own deployments without leaning too heavily on research produced by other surveillance programs.

If Claryx clears those gates, the company could help make invisible transmission legible while there is still time to act. The $3.5M Pre-Seed round gives the founders capital to pursue that proof. The next milestone is not a larger announcement. It is evidence that the hospital immune system can become dependable infrastructure inside the places where infection risk is highest.